
Oral semaglutide failed to slow Alzheimer's over 2 years in two phase III trials
Louis shares a MedPage Today report from CTAD that Alzheimer's patients on semaglutide (Rybelsus) in two phase III trials showed no significant improvement in cognitive or functional decline over 2 years versus placebo.


